Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.37 |
| ▸ | GABRP | O00591 | 1/20 | 0.37 |
| ▸ | GABRD | O14764 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7151514 | 0.81 | SOAT1 (0.40) | MAPTALDH1A1L3MBTL1POLBTSHR | |
| SCHEMBL14349236 | 0.79 | NUDT1 (0.50) | MAPTALDH1A1L3MBTL1ACACBGABRP | |
| SCHEMBL676002 | 0.78 | — | — | |
| SCHEMBL30078861 | 0.78 | — | — | |
| SCHEMBL129096 | 0.77 | UHRF1 (0.48) | ALDH1A1ACACBNOS1NOS2CRHR1 | |
| SCHEMBL3817033 | 0.77 | NQO1 (0.48) | MAPTALDH1A1HPGDTSHRNQO1 | |
| SCHEMBL171947 | 0.77 | TP53 (0.48) | MAPTALDH1A1L3MBTL1POLBTHRB | |
| SCHEMBL129095 | 0.75 | ACACB (0.37) | MAPTALDH1A1PROKR1HPGDACACB | |
| SCHEMBL30551571 | 0.75 | GABRA1 (0.45) | MAPTALDH1A1HPGDTSHRACACB | |
| SCHEMBL164636 | 0.75 | ACACB (0.37) | MAPTALDH1A1PROKR1HPGDACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1842847-B1 | PROCESS FOR PRODUCTION OF 5-CHLORO-2,4-DIHYDROXYPYRIDINE | TAIHO PHARMACEUTICAL CO LTD (JP) | 2012-03-07 | — | — | EP | disclosed |
| CN-102015699-A | Heterocyclic urea derivatives and methods of use thereof-211 | ASTRAZENECA AB | 2011-04-13 | — | — | CN | disclosed |
| US-7557216-B2 | Process for production of 5-chloro-2,4-dihydroxypyridine | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2009-07-07 | — | — | US | disclosed |
| US-7557216-B2 | Process for production of 5-chloro-2,4-dihydroxypyridine | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20090043101-A1 | PROCESS FOR PRODUCTION OF 5-CHLORO-2,4-DIHYDROXYPYRIDINE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2009-02-12 | — | — | US | disclosed |
| US-20090043101-A1 | PROCESS FOR PRODUCTION OF 5-CHLORO-2,4-DIHYDROXYPYRIDINE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2009-02-12 | — | — | US | disclosed |
| EP-1842847-A1 | PROCESS FOR PRODUCTION OF 5-CHLORO-2,4-DIHYDROXYPYRIDINE | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090043101-A1 | PROCESS FOR PRODUCTION OF 5-CHLORO-2,4-DIHYDROXYPYRIDINE | DPYD, DDT, HPD | MAPT 4166/4885ALDH1A1 155/4885L3MBTL1 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.